B2M and cancer: To block direct presentation, we used CRISPR to delete B2M from the cancer cells to generate cancer cells that were unable to express MHCI even following IFNg stimulation (Fig. 2ci), and these cells were unable to directly present antigen to tumor-specific CD8 T cells in vitro (Fig. 2cii).